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Abstract
Introduction The inflammatory response to an invading
pathogen in sepsis leads to complex alterations in hemostasis
by dysregulation of procoagulant and anticoagulant factors.
Recent treatment options to correct these abnormalities in
patients with sepsis and organ dysfunction have yielded
conflicting results. Using thromboelastometry (ROTEM®), we
assessed the course of hemostatic alterations in patients with
sepsis and related these alterations to the severity of organ
dysfunction.
Methods This prospective cohort study included 30
consecutive critically ill patients with sepsis admitted to a 30-
bed multidisciplinary intensive care unit (ICU). Hemostasis was
analyzed with routine clotting tests as well as
thromboelastometry every 12 hours for the first 48 hours, and at
discharge from the ICU. Organ dysfunction was quantified using
the Sequential Organ Failure Assessment (SOFA) score.
Results Simplified Acute Physiology Score II and SOFA scores
at ICU admission were 52 ± 15 and 9 ± 4, respectively. During
the ICU stay the clotting time decreased from 65 ± 8 seconds
to 57 ± 5 seconds (P = 0.021) and clot formation time (CFT)
from 97 ± 63 seconds to 63 ± 31 seconds (P = 0.017),
whereas maximal clot firmness (MCF) increased from 62 ± 11
mm to 67 ± 9 mm (P = 0.035). Classification by SOFA score
revealed that CFT was slower (P = 0.017) and MCF weaker (P
= 0.005) in patients with more severe organ failure (SOFA ≥ 10,
CFT 125 ± 76 seconds, and MCF 57 ± 11 mm) as compared
with patients who had lower SOFA scores (SOFA <10, CFT 69
± 27, and MCF 68 ± 8). Along with increasing coagulation
factor activity, the initially increased International Normalized
Ratio (INR) and prolonged activated partial thromboplastin time
(aPTT) corrected over time.
Conclusions Key variables of ROTEM® remained within the
reference ranges during the phase of critical illness in this cohort
of patients with severe sepsis and septic shock without bleeding
complications. Improved organ dysfunction upon discharge
from the ICU was associated with shortened coagulation time,
accelerated clot formation, and increased firmness of the
formed blood clot when compared with values on admission.
With increased severity of illness, changes of ROTEM®
variables were more pronounced.
Introduction
Organ failure contributes cumulatively to mortality in patients
with sepsis [1]. One of the mechanisms that is believed to con-
tribute to the pathogenesis of organ failure in sepsis is micro-
vascular thrombosis [2-5]. Pathways involved in the
prothrombotic state of critically ill patients include tissue fac-
tor-mediated thrombin generation and impaired anticoagulant
and fibrinolytic mechanisms [6]. Continuing consumption of
platelets and coagulation factors may cause overt dissemi-
nated intravascular coagulation and carry risk for bleeding dia-
thesis [7]. In severe inflammation, coagulation-regulating
systems appear to be defective, primarily as a result of
endothelial dysfunction [8,9]. However, the effect of anticoag-
ulant therapies on outcome is controversial [10-13].Page 1 of 8
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tests only incompletely mirror sepsis-induced coagulation
abnormalities, and hypercoagulation in particular is not
detected. More advanced laboratory analyses or experimental
methods to monitor coagulation in critically ill patients, includ-
ing tissue factor levels [14], prothrombin fragments F1 and F2
[15], thrombin-antithrombin (TAT) [16,17], and thrombomodu-
lin expression [18], have not yet been introduced into routine
clinical management.
End-points of routine coagulation tests occur early in the
hemostatic process, whereas thromboelastography measures
the viscoelastic characteristics of blood clot formation in a
whole blood assay, and it may therefore provide additional
information on coagulation. Thromboelastography assesses
the influence of plasmatic factors and platelets during all
phases of the coagulation process. Thus, it permits one to
evaluate the initiation of coagulation, the propagation of clot
formation, and the final firmness of the blood clot.
Thromboelastography has gained importance in the manage-
ment of bleeding disorders in trauma and surgical patients
[19-21]. It has also been used to evaluate alterations in
hemostasis in in vitro models of endotoxemia or at a single
time point in patients with sepsis [22-25]. However, the evolu-
tion of disorders of hemostasis measured by thromboelastog-
raphy during severe sepsis has not been investigated.
The aim of this study was to evaluate the evolution of coagula-
tion abnormalities using thromboelastometry (ROTEM® throm-
boelastometry; Pentapharm, Munich, Germany) in parallel with
routine coagulation tests during the early phase of severe sep-
sis and septic shock, and to relate these abnormalities to
organ dysfunction. We hypothesized that changes in
ROTEM® variables may be related to the evolution of organ
dysfunction. ROTEM® is a point-of-care device with limited
susceptibility to shock and vibrations.
Materials and methods
The study protocol for the present prospective cohort study
was approved by the regional governmental ethics committee
(Ethik Kommission des Kantons Bern). Written informed con-
sent was obtained from the patients or their relatives. Thirty
patients admitted to a 30-bed multidisciplinary intensive care
unit (ICU) with a diagnosis of sepsis (as defined by the recom-
mendations of the Society of Critical Care Medicine/European
Society of Intensive Care Medicine/American College of
Chest Physicians/American Thoracic Society/Surgical Infec-
tion Society International Sepsis Definitions Conference [26])
were enrolled in the study. Exclusion criteria were age under
18 years, pre-existent hematological disorders, current oral
anticoagulants, or therapy to inhibit platelet aggregation.
General treatment
All patients with sepsis were monitored with a radial arterial
line and a central venous line, and with a pulmonary artery
catheter if they were unresponsive to initial volume loading.
Treatment protocols were used for hemodynamic manage-
ment, weaning from mechanical ventilation, analgesia and
sedation, and insulin therapy. Thromboprophylaxis in all
patients was achieved with graduated compression stockings
or intermittent pneumatic compression devices in addition to
low-dose unfractionated heparin 10,000 units/day, in accord-
ance with the guidelines of the American College of Chest
Physicians for critically ill patients [27]. The heparin was
administered as a continuous intravenous infusion.
Volume resuscitation with colloids in our patients was
achieved with 6% hydroxyethyl starch 130/0.4 (Voluven®; Fre-
senius Kabi, Stans, Switzerland). Patients in the low Sequen-
tial Organ Failure Assessment (SOFA) group were
administered a mean of 1,373 ± 1,929 ml over the whole
study period; those in the high SOFA group received 2,523 ±
1,914 ml.
Data acquisition
Demographic data, source of infection, and length of stay in
the ICU were recorded. The Simplified Acute Physiology
Score II was determined on admission. The SOFA score was
assessed daily for the first 3 days after inclusion in the study
and on ICU discharge. The SOFA score was developed to
quantify the severity of illness based on the degree of organ
dysfunction [28].
Blood sampling
Blood samples were taken from a radial arterial line after 10 ml
blood had been discarded. Blood for thromboelastometry was
drawn into a 5 ml syringe and immediately anticoagulated with
0.5 ml trisodium citrate 0.106 mol/l (Sarstedt, Nümbrecht,
Germany).
Routine coagulation screening, including platelet count, Inter-
national Normalized Ratio (INR), activated partial thromboplas-
tin time (aPTT), levels of coagulation factors II, V, VII and X, and
fibrinogen, were measured daily for the first 3 days and upon
discharge. Routine coagulation laboratory measurements and
analysis of coagulation factor activity were performed using
the BCS® Analyzer and corresponding reagents (Siemens
Health Care Diagnostics, Düdingen, Switzerland).
Thromboelastometry
Thromboelastometry was performed using a ROTEM® ana-
lyzer (Pentapharm GmbH, Munich, Germany) every 12 hours
for 48 hours and at ICU discharge. The method, technique and
variables of thromboelastometry were described previously
[29]. Briefly, ROTEM® measures viscoelastic properties of clot
formation and fibrinolysis. Because of the use of a ball-bearingPage 2 of 8
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ment and vibration.
Tests were performed using ROTEM cups and pins. The
ROTEM® device was tested regularly for correct function
using quality control serum (ROTROL®; Pentapharm GmbH).
We conducted intrinsically and extrinsically activated tests
(INTEM and EXTEM), in accordance with the manufacturer's
recommendations (INTEM test: 20 μl CaCL2 0.2 mol/l, 20 μl
thromboplastin-phospholipid, 300 μl blood; EXTEM test: 20 μl
CaCL2 0.2 mol/l, 20 μl tissue factor, 300 μl blood). In order to
assess a possible effect of low-dose heparin administration to
our patients, we also analyzed the effects of addition of hepa-
rinase to the blood samples (HEPTEM test) and compared the
results with those of the INTEM test.
The influence of thrombocytes on clot firmness was estimated
with a platelet-inactivating test (FIBTEM test: 20 μl CaCL2 0.2
mol/l, cytochalasin D, 20 μl tissue factor, 300 μl blood). Chem-
icals and reagents were purchased from Pentapharm GmbH.
The variables that were measured using ROTEM® thromboe-
lastometry are the following. The clotting time (CT), the equiv-
alent to the reaction time (r time) of conventional TEG®
(Haemoscope, Skokie, IL, USA), represents the initiation of
coagulation. The propagation of clot formation, reflecting
thrombin generation and early fibrin polymerization, is charac-
terized by clot formation time (CFT), comparable to the clotting
time (k time) and alpha angle of conventional TEG®. CFT is
thereby defined as the time necessary to attain a clot firmness
of 20 mm. The maximal clot firmness (MCF), corresponding to
the maximal amplitude of conventional TEG®, which describes
the final strength of the clot, is influenced by the fibrinogen
concentration and the platelet count.
Statistical analysis
SigmaStat version 3.5 (Systat Software, Inc., Chicago, IL,
USA) was used for statistical analysis. After testing for normal
distribution (Kolmogorov-Smirnov test), data were analyzed
using analysis of variance for repeated measurements and the
Student-Newman-Keuls test for post hoc comparisons or,
where appropriate, Friedman analysis and the Dunn test. In
order to compare coagulation profiles in groups of patients
with different organ failure severity, patients were divided into
two groups using median SOFA score. Differences between
the two groups were analyzed using analysis of variance for
repeated measurements with one grouping factor (high versus
low SOFA score) and one within-subject factor (time). The
correlation between routine coagulation and ROTEM® varia-
bles with the severity of organ dysfunction defined by the
SOFA score was studied using the nonparametric Spearman
correlation (r) with pooled data from the continuous time
points. Comparison of the clotting times between the INTEM
and HEPTEM assays was analyzed with a two-sided t-test. For
all statistical tests, significance was assumed at P < 0.05. Val-
ues are expressed as mean ± standard deviation or median
(interquartile range) where appropriate.
Results
Patients
The characteristics of the included patients are shown in Table
1. Thirteen of the patients in the study suffered from severe
sepsis, and 17 patients from septic shock with hypotension
not reversed by volume resuscitation [26]. Median SOFA
score at ICU admission was 10. There were no thrombosis
and bleeding diathesis reported during the study period.
Routine laboratory results
Coagulation factor levels, routine coagulation tests, hemo-
globin, platelets, and white blood cell count are shown in Table
2. The means of aPTT and INR on admission were increased
beyond the normal range (Table 2). Relevant factor activities
Table 1
Characteristics of the study population
Parameter/variable Value
n 30
Age (years) 65 ± 13
Male sex (n) 19
Source of infection (n)
Lungs 9
Catheter related 3
Endocarditis 1
Abdominal 6
Soft tissue/bone 6
CNS 3
Unknown/other 2
SAPS II score 52.3 ± 14.6
APACHE II score 29.0 ± 7.7
SOFA score
Day 1 9.1 ± 4.0
Day 2 8.3 ± 3.8
Day 3 8.3 ± 4.2
Discharge 6.5 ± 3.7
Intensive care unit
Length of stay (days) 6 (3/11)a
Mortality (n [%]) 6 (20)
28 day survival (n [%]) 22 (73)
aLength of stay is presented as median (25%/75% percentiles). All 
other values are presented as number or as mean ± standard 
deviation.Page 3 of 8
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increased during the ICU stay. Only factor V remained close to
the midpoint of reference values. The platelet counts remained
within the normal range, but also increased over time. Fibrino-
gen levels and white blood count were raised above normal
during the entire stay in the critical care unit. Spearman rank
correlation between disease severity assessed by the SOFA
score and the routine coagulation tests INR and aPTT revealed
rather low coefficients (r = 0.39 and 0.51, respectively; P <
0.001 each).
Thromboelastometry
Thromboelastometric variables in the entire study cohort are
presented in Table 3. Average CT, CFT, and MCF remained
within the normal reference values established in a multicenter
study [30] (Table 3). However, during the time course of criti-
Table 2
Routine coagulation tests, clotting factor levels, hemoglobin, hematocrit, white blood count and CRP
Parameter Normal range Day 1 Day 2 Day 3 Discharge
Platelets (g/l) 140 to 380 191 ± 117 198 ± 135 196 ± 135 364 ± 201*
INR 0.9 to 1.15 1.18 ± 0.16 1.16 ± 0.18 1.12 ± 0.15 1.09 ± 0.14
aPTT (seconds) 25 to 36 48.1 ± 11.4 48.8 ± 13.0 44.7 ± 11.2 39.8 ± 11.6*
Fibrinogen (g/l) 1.3 to 3.6 6.2 ± 2.7 5.8 ± 1.6 5.5 ± 1.6 6.0 ± 4.4
Factor II (%) 81 to 134 61 ± 22 64 ± 25 69 ± 23 76 ± 28*
Factor V (%) 78 to 153 103 ± 45 110 ± 45 114 ± 43* 116 ± 33*
Factor VII (%) 70 to 139 66 ± 29 71 ± 29 88 ± 30* 79 ± 29
Factor X (%) 68 to 145 79 ± 29 81 ± 30 90 ± 22 84 ± 21
Hemoglobin (g/l) 121 to 154 100.4 ± 14.3 98.8 ± 14.7 98.9 ± 11.6 102.2 ± 12.2
Hematocrit (%) 0.36 to 0.44 29.1 ± 4.4 29.1 ± 4.8 29.2 ± 3.8 30.4 ± 3.7
WBC (g/l) 3.5 to 10.5 16.1 ± 7.5 17.4 ± 7.3 17.0 ± 6.4 16.6 ± 6.9
CRP (mg/l) <5 201 ± 87 202 ± 83 176 ± 94 113 ± 76*
Creatinine (μmol/l) 59 to 104 172 ± 120 159 ± 113 171 ± 115 151 ± 126
Bilirubin (μmol/l) 3 to 26 33.3 ± 34.3 37.0 ± 40.5 40.0 ± 46.2 32.8 ± 43.9
Values are expressed as Mean ± SD. *P < 0.05, versus baseline. aPTT, activated partial thromboplastin time; CRP, C-reactive protein; INR, 
International Normalized Ratio; WBC, white blood count.
Table 3
Results of thromboelastometry
Parameter Normal ranges 0 hours 12 hours 24 hours 36 hours 48 hours Discharge Spearman
r P
CT-EXTEM 42 to 74 64.9 ± 7.6 66.0 ± 10.6 61.7 ± 9.6 63.7 ± 7.2 61.9 ± 7.3 57.4 ± 4.6* 0.09 0.36
CT-INTEM 137 to 246 195.9 ± 25.8 201.0 ± 31.4 199.8 ± 36.7 213.2 ± 41.1 216.3 ± 43.8 206.7 ± 40.6
CT-HEPTEM 137 to 246 197.1 ± 39.3 217.2 ± 58.1 212.2 ± 47.7 212.4 ± 40.0 205.8 ± 29.6 192.8 ± 34.2
CFT-EXTEM 46 to 148 97.0 ± 62.6 103.6 ± 79.2 99.3 ± 61.0 100.4 ± 64.8 94.5 ± 54.9 62.6 ± 30.7* 0.64 0.001
Alpha-EXTEM 63 to 81 73.9 ± 7.8 74.3 ± 7.1 74.0 ± 6.9 73.7 ± 6.8 74.5 ± 5.9 78.3 ± 4.1 -0.58 0.001
MCF-EXTEM 49 to 71 62.1 ± 11.2 62.1 ± 12.6 62.1 ± 12.1 62.1 ± 12.4 62.7 ± 11.6 67.4 ± 9.0* -0.63 0.001
MCF-INTEM 52 to 72 63.7 ± 8.0 63.2 ± 7.6 61.9 ± 8.3 64.1 ± 7.7 64.6 ± 8.1 66.9 ± 8.4
MCF-HEPTEM 52 to 72 61.0 ± 8.9 59.6 ± 8.0 59.1 ± 9.4 60.6 ± 9.2 61.5 ± 8.4 64.1 ± 7.8*
Spearman rank correlation (r) is between the continuous values of Sequential Organ Failure Assessment (SOFA) score with thromboelastometric 
variables. *P < 0.05, versus baseline. alpha angle (°); CFT, clot formation time (seconds); CT, clotting time (seconds); EXTEM, activation of 
coagulation with tissue factor; HEPTEM, inhibition of heparin with heparinase; INTEM, activation of coagulation with thromboplastin; MCF, 
maximal clot firmness (mm).Page 4 of 8
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in MCF in the tissue factor activated tests (EXTEM) compared
with admission values (Table 3).
In patients with higher scores for organ failure, MCF differed
from the low SOFA group during the first 48 hours. This differ-
ence had resolved by the time of discharge (Figure 1). CT did
not differ between groups (Figure 2). Clot propagation, char-
acterized by CFT and alpha angle, was significantly slowed in
the group with the higher organ dysfunction scores compared
with the low SOFA group during the first 48 hours (Figures 3
and 4). However, after 48 hours the values in the two groups
converged.
Platelet inhibition with cytochalasin revealed stronger impair-
ment of MCF in the high SOFA group (Figure 5). The relative
contribution of the fibrin clot (after inhibition of the platelet con-
tribution with cytochalasin) remained stable during the ICU
stay. No differences in the clotting time were noted between
the HEPTEM and the INTEM assay results.
The variables of ROTEM® thromboelastometry CFT, alpha
angle, and MCF correlated moderately with disease severity
defined by the SOFA score (Table 3).
Discussion
The coagulation system is commonly activated during sepsis
as a result of crossreactions with the inflammatory system
[5,31]. In the present cohort study we assessed coagulation
abnormalities in septic patients during the critical phase of the
illness using ROTEM® thromboelastometry. In order to evalu-
ate further the relationship between perturbation of the coag-
ulation system and organ dysfunction, we divided the cohort at
the median of the initial SOFA score and compared the result-
ing two groups.
Improvements in SOFA scores of these patients were associ-
ated with shortened time to initiation of coagulation, acceler-
ated clot formation, and improved firmness of the final clot at
ICU discharge when compared with values on admission.
Therefore, we hypothesize that the coagulation system has
recovered toward the patients' individual baselines upon dis-
charge from the ICU. Nevertheless, key thromboelastometric
variables for the patients in our study remained within the
Figure 1
Maximal clot firmness. *P < 0.05, differences between groups; #P < 
0.05, difference from baseline value in the high Sequential Organ Fail-
ure Assessment (SOFA; ≥ 10) group. EXTEM, activation of coagulation 
with tissue factor; MCF, maximal clot firmness.
Figure 2
Clotting time. EXTEM, activation of coagulation with tissue factor; 
SOFA, Sequential Organ Failure Assessment.
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Figure 3
Clot formation timei . *P < 0.05, differences between groups; #P < 0.05, 
difference from baseline value in the high Sequential Organ Failure 
Assessment (SOFA; ≥ 10) group. CFT, clot formation time; EXTEM, 
activation of coagulation with tissue factor.Page 5 of 8
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[30]. In this context, no signs of overt disseminated intravascu-
lar coagulation with adverse bleeding events were observed.
Of note, compared with the increase in clot firmness, the rise
in the platelet count during the course of critical illness was
disproportionately high, whereas fibrinogen levels remained
constant. This underlines the observation that fibrinogen levels
appear to have a much greater impact on MCF than do
changes in platelet count [32,33].
The results of ROTEM® thromboelastometry in the present
study did not suggest hypercoagulability in terms of reduced
CT, reduced CFT, or increased MCF compared with estab-
lished normal ranges [30,34-37]. The mean of the MCF in the
FIBTEM assay of the patients with a SOFA score less than 10
was slightly higher than the reported normal range. However,
because the FIBTEM assay measures only an isolated compo-
nent of the overall clot firmness, it may probably not be used
as a reliable parameter for hypercoagulability. In this respect,
our results differ from the thromboelastographic data reported
in a study by Gonano and coworkers [38], who described
hypercoagulability based on their results of decreased r and k
values using TEG®. Two other studies employing sepsis mod-
els also came to the conclusion that lipopolysaccharide-
induced hypercoagulability may be detected by thromboelas-
tography [22,23]. Spiel and coworkers [22] administered a
bolus injection of endotoxin to healthy volunteers and demon-
strated a transient decrease in the coagulation time, limited to
the first 24 hours after injection, accompanied by increased
markers of coagulation activation (increased levels of pro-
thrombin fragments F1+2) [22]. Incubation of whole blood of
healthy volunteers with endotoxin also produced a decrease in
clotting time [23]. Clearly, the two latter investigations meas-
ured the effect of lipopolyaccharide on hemostasis in highly
standardized models reflecting the very early phase after
induction of inflammation. However, the clinical scenario of
critically ill patients admitted to an ICU differs from these situ-
ations.
In critically ill patients with severe sepsis and septic shock, the
disease has reached a more advanced stage – with advanced
inflammatory response and sustained exposure to the infec-
tious pathogen – by the time they present at the ICU. In the
clinical setting, assessment of activation of coagulation by
thromboelastography may thus not present with shortening of
CT and CFT but rather with a development in the opposite
direction, in which coagulation factors are consumed. A con-
comitant decrease in the production of clotting factors due to
hepatic dysfunction in sepsis may also play a role, however
[39].
Our data are supported by an analysis of the placebo group in
the PROWESS (Recombinant Human Protein C Worldwide
Evaluation in Severe sepsis) study, which demonstrated that
increased severity of sepsis is accompanied by prolonged
coagulation times, suggesting decreased activity of coagula-
tion factors as a result of increased consumption [40].
Activation of coagulation is a well-known pathophysiological
process in sepsis [5,14-17,31]. That accelerated clot forma-
tion and increased clot strength were not present in our study
by no means excludes activation of coagulation in sepsis. The
more likely explanation for our findings is that inappropriate
activation of coagulation may be depicted by thromboelastog-
raphy only at an early and possibly preclinical phase. However,
Figure 4
Alpha angle. *P < 0.05, differences between groups; #P < 0.05, differ-
ence from baseline value in the high Sequential Organ Failure Assess-
ment (SOFA; ≥ 10) group. EXTEM, activation of coagulation with tissue 
factor.
Figure 5
Maximal clot firmness after platelet inhibition with cytochalasin D (FIBTEM)
(FIBTEM). The normal range for maximal clot firmness (MCF) is 9 to 25 
mm [30]. *P < 0.05, differences between groups. SOFA, Sequential 
Organ Failure Assessment.Page 6 of 8
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graphic signs of hypercoagulation may be absent.
There is concern that the administration of colloids may have
affected the coagulation system. Although the doses of fluid
resuscitation with 6% hydroxethyl starch 130/0.4 differed
between the two groups, the administered volumes have
reportedly only minor effects on parameters of thromboelas-
tography [41,42].
A low-dose regimen of unfractionated heparin was adminis-
tered to the patients in the present study in order to prevent
thromboembolic complications. This could have influenced
thromboelastography analysis. However, in a heparinase
assay (ROTEM® HEPTEM) we analyzed clotting time as the
variable of interest in this context and excluded such an effect
[43]. These results suggest that the low dose of heparin used
for thromboprophylaxis may not be detected by thromboelas-
tography.
A limitation of our study is that the reported changes of
ROTEM® parameters had to be interpreted on the basis of
external reference values. Future investigations in a controlled
study may reveal clearer relationships between organ dysfunc-
tion and the coagulation system assessed by thromboelastog-
raphy.
Conclusions
Key variables for ROTEM® remained within the reference
ranges during the phase of critical illness in this cohort of
patients with severe sepsis and septic shock without bleeding
complications. Although average thromboelastometry varia-
bles did not provide additional information to standard coagu-
lation tests, certain dynamics of ROTEM® variables were
noted within the reference ranges. Improved organ dysfunc-
tion upon discharge from the ICU was associated with short-
ened coagulation time, accelerated clot formation, and
increased firmness of the formed blood clot when compared
with values on admission. With increased severity of illness,
changes of ROTEM® variables were more pronounced.
Thromboelastography performed in patients with severe sep-
sis cannot reliably detect activation of coagulation in the sense
of a hypercoagulable state. Further studies in patients with
sepsis are warranted to investigate the role of thromboelastog-
raphy in relation to bleeding and thromboembolic complica-
tions as end-points.
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